

What is claimed is:

1. An anti-hemagglutinin (HA) antibody molecule comprising (a) a heavy chain variable region segment comprising the CDR1, CDR2, and CDR3 of the heavy chain variable region VH123; and (b) a light chain variable region segment comprising the CDR1, CDR2, or CDR3 of the light chain variable region VK-65.

2. The antibody molecule of claim 1, further comprising an Fc region.

3. The antibody molecule of claim 2, wherein the Fc region comprises a mutation.

4. The antibody molecule of any of claims 1-3, comprising an Fc region comprising the mutations of FcMut215.

5. The antibody molecule of any of claims 1-4, wherein the heavy chain variable region segment comprises one, two, three, or all of the FR1, FR2, FR3, or FR4 of the heavy chain variable region VH123.

6. The antibody molecule of any of claims 1-4, wherein the heavy chain variable region segment comprises one, two, three, or all of the FR1, FR2, FR3, or FR4 of the heavy chain variable region VH148.

7. The antibody molecule of any of claims 1-4, wherein the heavy chain variable region segment comprises one, two, three, or all of the FR1, FR2, FR3, or FR4 of the heavy chain variable region VH175.

8. The antibody molecule of any of claims 1-7, comprising the amino acid sequence of heavy chain variable region VH123, VH148, or VH175, or an amino acid sequence at least 85%, 90%, or 95% identical thereto.

9. The antibody molecule of claim 8, comprising the amino acid sequence of heavy chain variable region VH123, or an amino acid sequence at least 85%, 90%, or 95% identical thereto.

10. The antibody molecule of claim 8, comprising the amino acid sequence of heavy chain variable region VH148, or an amino acid sequence at least 85%, 90%, or 95% identical thereto.

11. The antibody molecule of claim 8, comprising the amino acid sequence of heavy chain variable region VH175, or an amino acid sequence at least 85%, 90%, or 95% identical thereto.
12. The antibody molecule of any of claims 1-11, wherein the light chain variable region segment comprises one, two, three, or all of the FR1, FR2, FR3, or FR4 of the light chain variable region VK-65.
13. The antibody molecule of any of claims 1-12, comprising the amino acid sequence of light chain variable region VK-65, or an amino acid sequence at least 85%, 90%, or 95% identical thereto.
14. An anti-hemagglutinin (HA) antibody molecule comprising (a) the heavy chain variable region VH123; (b) the light chain variable region VK-65; and (c) an Fc region comprising FcMut215.
15. An anti-hemagglutinin (HA) antibody molecule comprising (a) the heavy chain variable region VH148; (b) the light chain variable region VK-65; and (c) an Fc region comprising FcMut215.
16. An anti-hemagglutinin (HA) antibody molecule comprising (a) the heavy chain variable region VH175; (b) the light chain variable region VK-65; and (c) an Fc region comprising FcMut215.
17. A pharmaceutical composition comprising the antibody molecule of any of claims 1-16 and a pharmaceutically acceptable carrier.
18. A nucleic acid encoding a heavy chain variable region segment, a light chain variable region segment, or both, of the antibody molecule of any of claims 1-16.
19. A vector comprising the nucleic acid of claim 18.
20. A cell comprising the nucleic acid of claim 18 or the vector of claim 19.
21. A method of producing an antibody molecule, comprising culturing the cell of claim 20 under conditions that allow production of the antibody molecule, thereby producing the antibody molecule.
22. A kit comprising the antibody molecule of any of claims 1-16 and instructions for use.

23. A method of treating or preventing an influenza virus infection, or a symptom thereof, in a subject, comprising administering to the subject an effective amount of the antibody molecule of any of claims 1-16.

24. The method of claim 23, which prevents an influenza virus infection, optionally wherein the method prevents an influenza virus infection for at least 5, 10, 15, 20, 25, 30, 40, 45, 50, 60, 70, 80, 90, 100, 150, 200 days or more.

25. The method of claim 23 or 24, wherein the subject is at risk of having an influenza infection.

26. The method of any of claims 23-25, wherein the antibody molecule is administered before the subject is exposed to an influenza virus.

27. The method of any of claim 23-26, wherein the antibody molecule is administered subcutaneously or intramuscularly.

28. The method of any of claims 23-27, wherein the antibody molecule is administered once during an influenza season.

29. The method of any of claims 23-28, wherein the influenza virus is an influenza A virus.

30. The method of claim 29, wherein the influenza virus is an H1 or H3 influenza virus.